Home > Archive > 2014 > 2

Volume 33, Number 2, pages 6-11

Pharmacologic Treatment of Prediabetes

Katia Cristina Portero McLellan, Ph.D., Kathleen Wyne, M.D., Ph.D., F.A.C.E., Evangelina Trejo Villagomez, Ph.D., And Willa A. Hsueh, M.D.

The International Diabetes Federation has attempted to estimate the prevalence of prediabetes, which is currently at 316 million people globally, although this is likely a dramatic underestimation. Prediabetes is a recognized risk factor for both diabetes and cardiovascular disease. Slowing the epidemic of diabetes, and its associated economic burden of microvascular and macrovascular complications, requires identification and treatment of prediabetes. This review will focus on the data using pharmacologic therapy to slow the progression from prediabetes to Type 2 diabetes.

Drug treatment
Prediabetes